Moderate

Hypertriglyceridaemia management

High triglycerides · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Hypertriglyceridaemia ranges from a cardiovascular risk modifier to a cause of acute pancreatitis at very high levels. Management addresses secondary causes, lifestyle, glycaemic control and, when severe, triglyceride-lowering drugs.

Red flags

  • Severe abdominal pain (hypertriglyceridaemic pancreatitis)
  • Triglycerides >10 mmol/L
  • Eruptive xanthomata and lipaemia retinalis
  • Altered mental status with lipaemic serum
  • Recurrent pancreatitis episodes

Assessment

Differential diagnosis

  • Secondary (diabetes, alcohol, hypothyroidism, obesity)
  • Familial hypertriglyceridaemia
  • Familial combined hyperlipidaemia
  • Familial chylomicronaemia syndrome
  • Drug-induced (oestrogen, steroids, retinoids, antipsychotics)
  • Nephrotic syndrome / renal disease

Investigations

  • Fasting triglyceride and full lipid profile
  • HbA1c / fasting glucose
  • TSH
  • Liver and renal function, urine protein
  • Amylase/lipase if abdominal pain (pancreatitis)
  • Review of alcohol intake and medications

Management

  • Classify severity: mild-moderate (<10 mmol/L) versus severe (≥10 mmol/L)
  • Identify and treat secondary causes — diabetes, alcohol, drugs, hypothyroidism
  • Emphasise diet (reduce refined carbohydrate, alcohol, fat), weight loss and exercise
  • Optimise glycaemic control in diabetes
  • For cardiovascular risk with TG 1.5-5.6 mmol/L on statin, consider icosapent ethyl
  • Add a fibrate when TG remains very high despite lifestyle measures
  • For TG ≥10 mmol/L, prioritise pancreatitis prevention with fibrate and very low-fat diet
  • Admit for very severe hypertriglyceridaemia with pancreatitis for IV insulin ± apheresis
  • Continue statin for LDL/non-HDL goals where indicated
  • Avoid drugs that raise triglycerides where alternatives exist
  • Screen family in suspected genetic chylomicronaemia
  • Follow up triglycerides after each intervention

Drugs & doses

Fenofibrate 145 mg PO OD (reduce in renal impairment)
Icosapent ethyl 2 g PO BD (high-purity EPA)
Omega-3 acid ethyl esters 2-4 g PO daily
Atorvastatin 20-40 mg PO OD for concurrent LDL control
Insulin infusion for severe hypertriglyceridaemic pancreatitis (hospital)
Gemfibrozil 600 mg PO BD (avoid combining with statin where possible)

Disposition

GP or lipid clinic management. Admit severe hypertriglyceridaemia with pancreatitis; refer suspected genetic disorders.

Complications & pitfalls

  • Acute pancreatitis
  • Chronic pancreatitis
  • Atherosclerotic cardiovascular disease
  • Hepatic steatosis
  • Spuriously altered lab results from lipaemia

Exam pearls

  • Fibrates, not statins, are first-line when the priority is preventing pancreatitis
  • Combining gemfibrozil with a statin markedly raises myopathy risk — prefer fenofibrate
  • Icosapent ethyl (not mixed fish oils) reduced cardiovascular events in REDUCE-IT
  • Alcohol can dramatically raise triglycerides — abstinence is powerful
  • Non-HDL cholesterol is the better target when triglycerides are high

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.